Hogan Lovells

Xin Tao

Counsel

Washington, D.C.

Phone

+1 202 637 6986

Fax

+1 202 637 5910

Email

xin.tao@hoganlovells.com

Biography

With a strong understanding of life sciences, Xin Tao works closely with clients in the food and drug industries to navigate the evolving regulatory environments and develop innovative strategies to commercialize products made with emerging technologies in the United States.

Xin's previous work experience as a lab research biochemist informs his science-based food and drug law practices. His unique ability in understanding and interpreting the complex scientific issues as they relate to the governing legal and regulatory requirements helps clients with all phases of product development, manufacturing, and marketing. His practice focuses on novel food and drug applications that require U.S. Food and Drug Administration (FDA) review and FDA Current Good Manufacturing Practices (cGMP) compliance for foods, dietary supplements, and pharmaceuticals. Xin has extensive experience advising companies and investors on developing and marketing alternative plant proteins, microbial and animal cell-based technologies.

Born and raised in China, Xin is well-equipped to assist global companies to adapt to China's National Medical Products Administration's (NMPA), formerly known as China Food and Drug Administration (CFDA), ever-changing regulatory regime.

During law school, Xin worked as a regulatory scientist at an international law firm and served as an executive editor of the *Georgetown Environmental Law Review*.

Languages

Mandarin

Practices

Food Law

Pharmaceuticals and Biotechnology Regulatory

Industries

Consumer

Life Sciences and Health Care

Areas of focus

Consumer Product Safety Regulation

Medical Foods and Dietary

Representative experience

Obtained FDA's favorable review of intended uses of novel food additives, generally recognized as safe substances (GRAS), and food contact substances (FCS) in foods and beverages.

Helped food and pharmaceutical companies develop effective regulatory compliance strategy when responding to FDA Form 483 observations/warning letters.

Developed legal strategies in helping consumer products companies and trade associations establish compliance with California's Proposition 65 warning.

Helped global life sciences companies respond to NMPA enforcement actions and advised on premarket strategy of new drug products and drug recalls in China.

Advised various private equity funds, investment banks, and global food and pharmaceutical companies in conducting FDA and NMPA regualtory compliance due diligence reviews.

Awards and rankings

- Rising Stars, Washington, D.C. Food and Drug Law, *Super Lawyers*, 2020-2021

Latest thinking and events

- News
  - FDA cites five companies for illegally selling Delta-8 THC and CBD products
- Sponsorships and Speaking Engagements
  - Legal, regulatory, and compliance forum on dietary supplements
- News
  - New Acrylamide Prop 65 lawsuits: preliminary injunction reinstated; proposed regulation disapproved
- Sponsorships and Speaking Engagements
  - Trends in Legal Services Markets in the U.S. and

Supplements

Food Advertising and Regulation

Food Recalls

International Regulatory Compliance

Food Legislation and Regulatory Policy Development

Product Development and Approval

Food Compliance and Enforcement

Hogan Lovells China Desk

Regulatory Inspections and cGMP

Cell, Tissue, and Gene Therapies

Education and admissions

Education

J.D., Georgetown University Law Center, 2012

M.S., Texas A&M University, 2009

B.S., Shanghai Jiaotong University, 2006

Bar admissions and qualifications

District of Columbia

Virginia (inactive)

China: Insights from Practitioners

- News
  - With the U.S. PFAS “Phase-out” clock ticking, what every food company should know
- News
  - FDA updates on efforts to assist U.S. companies with China’s new food facility regulation